Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin-alfa to Allow Higher Doses of Ribavirin in Chronic Hepatitis C
NCT00248339Phase 3Completed
- Sponsor
- Virginia Commonwealth University
- Start
- May 2002
- Primary completion
- Jul 2005
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of epoetin alfa in hepatitis C (HCV) (3 arms), sponsored by Virginia Commonwealth University. Primary endpoint: Mean dose of ribavirin utilized at 18 months. Started May 2002; status: completed.
02
Drugs
epoetin alfa
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00248339.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00248339.